Olmesartan Medoxomilo + Hidroclorotiazida Fantex (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Fantex, is an angiotensin II receptor blocker presented as a tablet for oral use. It is combined with hydrochlorothiazide, a thiazide‑type diuretic, to help lower blood pressure in adults with hypertension.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Fantex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil combined with hydrochlorothiazide is used in the management of hypertension, acting on the renin‑angiotensin‑aldosterone system to reduce elevated blood pressure. - Hypertension: improves blood pressure control when monotherapy is insufficient. - Diastolic hypertension: lowers diastolic pressure to target levels. - Resistant hypertension: provides additional diuretic effect to achieve therapeutic goals. - Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction in hypertensive patients. - Edema associated with hypertension: reduces fluid retention through the diuretic component.

Olmesartan Medoxomilo + Hidroclorotiazida Fantex may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia or severe electrolyte imbalance. - Angio‑edema involving face, lips or tongue. - Liver enzyme elevation. - Blood dyscrasias such as neutropenia.

When prescribing Olmesartan Medoxomilo + Hidroclorotiazida Fantex, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially with diuretic use. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant potassium‑sparing agents: monitor for hyperkalemia. - Hypotension risk: caution in patients with volume depletion or on other antihypertensives. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomilo + Hidroclorotiazida Fantex interacts with several medicines that can modify its efficacy or safety.

Major Interactions (Avoid): - Aliskiren combined with an ARB in diabetic patients – increased risk of renal impairment. - Potassium supplements or potassium‑sparing diuretics – risk of hyperkalemia. - Lithium – may increase lithium serum concentrations.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may reduce antihypertensive effect and affect renal function. - Cyclosporine or tacrolimus – can increase serum levels of olmesartan. - Antidiabetic agents – may enhance glucose‑lowering effect, requiring dose adjustment.